DesoxypeganineCAS# 495-59-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 495-59-0 | SDF | Download SDF |
PubChem ID | 442894 | Appearance | Powder |
Formula | C11H12N2 | M.Wt | 172.23 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline | ||
SMILES | C1CC2=NC3=CC=CC=C3CN2C1 | ||
Standard InChIKey | WUFQLZTXIWKION-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C11H12N2/c1-2-5-10-9(4-1)8-13-7-3-6-11(13)12-10/h1-2,4-5H,3,6-8H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Desoxypeganine is being developed for its potential utility in the pharmacological treatment of alcohol abuse to reduce craving and depression in alcohol abusers, and might also be useful as a smoking cessation aid. 2. Desoxypeganine is a cholinesterase inhibitor, acting preferentially on butyrylcholinesterase, and as a selective inhibitor of monoamine oxidase A but not monoamine oxidase B. |
Targets | MAO |
Desoxypeganine Dilution Calculator
Desoxypeganine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.8062 mL | 29.0309 mL | 58.0619 mL | 116.1238 mL | 145.1547 mL |
5 mM | 1.1612 mL | 5.8062 mL | 11.6124 mL | 23.2248 mL | 29.0309 mL |
10 mM | 0.5806 mL | 2.9031 mL | 5.8062 mL | 11.6124 mL | 14.5155 mL |
50 mM | 0.1161 mL | 0.5806 mL | 1.1612 mL | 2.3225 mL | 2.9031 mL |
100 mM | 0.0581 mL | 0.2903 mL | 0.5806 mL | 1.1612 mL | 1.4515 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Nodakenetin
Catalog No.:BCN5604
CAS No.:495-32-9
- Nodakenin
Catalog No.:BCN2378
CAS No.:495-31-8
- Ammijin
Catalog No.:BCN3617
CAS No.:495-30-7
- Auraptene
Catalog No.:BCN5603
CAS No.:495-02-3
- Ginsenoside Rk1
Catalog No.:BCN3552
CAS No.:494753-69-4
- TC-G 1001
Catalog No.:BCC6316
CAS No.:494191-73-0
- Nornicotine
Catalog No.:BCN8176
CAS No.:494-97-3
- Isoammodendrine
Catalog No.:BCN2146
CAS No.:494-15-5
- Nifuratel
Catalog No.:BCC1800
CAS No.:4936-47-4
- Methyl L-pyroglutamate
Catalog No.:BCN7060
CAS No.:4931-66-2
- Savinin
Catalog No.:BCN5602
CAS No.:493-95-8
- α-D-Glucose
Catalog No.:BCC9197
CAS No.:492-62-6
- Tropine isobutyrate
Catalog No.:BCN1923
CAS No.:495-80-7
- Valtropine
Catalog No.:BCN1926
CAS No.:495-82-9
- Tigloyltropeine
Catalog No.:BCN1944
CAS No.:495-83-0
- (+)-Methysticin
Catalog No.:BCN8429
CAS No.:495-85-2
- Org 25543 hydrochloride
Catalog No.:BCC6288
CAS No.:495076-64-7
- 11alpha,12alpha-Oxidotaraxerol palmitate
Catalog No.:BCN7129
CAS No.:495389-95-2
- Estradiol heptanoate
Catalog No.:BCC8961
CAS No.:4956-37-0
- Fenofibrate
Catalog No.:BCC4781
CAS No.:49562-28-9
- Benzofuran-2-carboxylic acid
Catalog No.:BCC8851
CAS No.:496-41-3
- Pyromeconic acid
Catalog No.:BCN7177
CAS No.:496-63-9
- Helicianeoide A
Catalog No.:BCN2486
CAS No.:496066-82-1
- Helicianeoide B
Catalog No.:BCN2487
CAS No.:496066-89-8
Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses.[Pubmed:18560630]
Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
Desoxypeganine (DOP) is a natural alkaloid that has been characterized as a cholinesterase inhibitor and a selective inhibitor of monoamine oxidase A. DOP has been investigated for its potential utility in the pharmacological treatment of alcohol abuse and as a smoking cessation aid. The aim of this clinical trial was to evaluate the tolerance and single-dose pharmacokinetic profile of DOP in healthy human volunteers. The study was an open-label, dose-escalation, phase I clinical trial involving the administration of increasing single oral doses of DOP (50, 100, 150 and 200 mg). The study was conducted according to the Declaration of Helsinki and Good Clinical Practice. Eighteen healthy adult volunteers (8 males and 10 females, age ranging 20-30 years) were recruited. DOP was administered sequentially, escalating in single doses of 50, 100, 150 and 200 mg in four experimental sessions with a washout period of at least 1 week between them. Progress to the next dose was allowed only if the previous dose was tolerated. Pharmacokinetic parameters were determined using noncompartmental methods. Clinical and analytical safety was assessed throughout the study, and QTc intervals were measured at regular intervals. The main pharmacokinetic parameters and renal excretion are described. No serious adverse events were registered, and none of the subjects discontinued the study because of lack of tolerance. All the adverse events recorded were mild to moderate and increased with the dose. The ECG measurements revealed that even at a higher dose, the QTc interval remained below the safety threshold. In summary, this first phase I study indicates that DOP has linear and dose-proportional pharmacokinetics, satisfactory oral bioavailability and plasma half-life and renal excretion. Also, DOP has shown an adequate safety profile that allows the continuation of clinical development.
Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.[Pubmed:19640356]
Int J Clin Pharmacol Ther. 2009 Jul;47(7):483-90.
UNLABELLED: Desoxypeganine, a naturally occurring alkaloid, is being developed for its potential utility in the pharmacological treatment of alcohol abuse to reduce craving and depression in alcohol abusers, and might also be useful as a smoking cessation aid. During the preclinical development it was characterized as a cholinesterase inhibitor, acting preferentially on butyrylcholinesterase, and as a selective inhibitor of monoamine oxidase A but not monoamine oxidase B. OBJECTIVE: The aim of the present human pharmacology clinical trial was to assess the oral bioavailability, pharmacokinetic profile and tolerability of Desoxypeganine, administered in a multiple-dose regimen to healthy volunteers. SUBJECTS AND METHODS: Eighteen healthy adult volunteers of both sexes received placebo, 50 mg and 100 mg Desoxypeganine (b.i.d. for 3 days) in a single-blind, crossover, randomized manner. Main pharmacokinetic parameters after single and multiple doses were estimated. Clinical tolerability and clinical laboratory safety, including effect on QTc interval, were assessed. RESULTS: Non-compartmental estimations of Cmax, AUC, tmax, t1/2 and MRT at 12-h intervals are given. No significant dose effect was observed in tmax, t1/2 and MRT. Cmax and AUC are approximately double with the dose of 100 mg comparing with the dose of 50 mg. A significant increase (p < 0.05) on Cmax and AUC was also obtained with the highest dose administered in comparison with the lowest one, revealing a slight but clinically insignificant accumulation. Steady state of drug concentration was reached in both genders during the study period. Plasma protein binding of Desoxypeganine amounted to approximately 18%. No severe adverse events were recorded and none of the subjects suffered from any adverse event that led to withdrawal from the study. Most frequently recorded adverse event was dizziness. No significant effects of Desoxypeganine on vital signs, laboratory parameters or QTc interval were observed. CONCLUSIONS: The present clinical trial describes the pharmacokinetic profile of two doses of Desoxypeganine, administered orally in multiple dose to healthy volunteers. The drug was well tolerated without any severe clinical, clinical laboratory, or ECG adverse events being recorded.